Management of Side-Effects of Anti-Acne Treatment by a Cosmetic Routine
NCT ID: NCT05486910
Last Updated: 2022-08-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
44 participants
OBSERVATIONAL
2021-04-29
2021-07-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The tested regimen (cream and cleanser) has been specifically developed to rebalance the skin microbiome and compensate side-effects of topical treatments (hydration, skin barrier repair) together with an action on skin imperfections and marks.
This open-label study was conducted in subjects aged 12 years and over with sensitive skin (\>2 on a sensitivity composite score from 0-3) treated for at least one month with the fixed-dose gel combination and presenting with treatment-related skin intolerance.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Tolerance of Formula 609613 37 in Acneic Patients
NCT05469880
Efficacy and the Tolerability of the Sequential Application of Two Marketed Products in Patients With Acne Vulgaris
NCT01461655
Efficacy, Safety Profile, and Post-Acne Sequelae of 0.025% Retinoic Acid Cream vs. 0.1% Adapalene Cream in Mild Acne Vulgaris in Fitzpatrick Skin Types III-V
NCT07015931
Retinyl Palmitate-loaded Ethosomes in Acne Vulgaris
NCT04080869
Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%
NCT00599521
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Each study report is subjected to a quality inspection by a proofreader member of Dermscan not involved in the audited study. The inspection of the study report allows to confirm that the results reflect exactly the study raw data and that the study fulfills any standard and regulatory requirements.
Regarding the statistical analysis, data obtained for each parameter, at each measurement time and on each zone are presented in raw value tables. The tables also show the descriptive statistics: means, medians, minima, maxima, standard errors of the means (SEM), confidence intervals of 95% (CI 95%) of these values as well as the variations and percentage variations. They also present the results of the statistical analysis.
Participants have the right to exit from the study at any time and for any motive in compliance with the Helsinki Declaration (1964) and its successive updates. The investigator can also interrupt the subject participation in the study prematurely in the case of a disease occurrence, a pregnancy or the occurrence of an adverse reaction.
The personnel in charge of the study collects data into individual case report forms in electronic or paper format and/or directly from measurement software. When information is collected in paper format, the double data entry is then done from these supports by the designed operator(s), without any interpretation, in specific EXCEL databases. The Project Manager or assistant checks the double data entry by comparing both databases. Then the coherence of the whole data set is checked as well as formulas used in the EXCEL tables (calculation formulas, selected data…). When all the controls are done, the database is locked.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* phototype I to IV
* subject under EPIDUO® with a failed cosmetic routine for more than 1 month.
* subject agreeing to change their routine (introduction of the EFFACLAR routine).
* subjects with moderate skin sensitivity: composite score \>2 at the inclusion (burning sensation, tightness and itching) with 4 grades: absent, slight, medium and severe
* subject under anti-acne treatment since 1 month, with an usual routine in failure
* subject who presents irritated skin due to EPIDUO® treatment
Exclusion Criteria
* cutaneous pathology on the studied zone other than acne (eczema etc.)
• use of topical or systemic treatment during the previous weeks liable to interfere with the assessment of the cutaneous acceptability of the study product (according to the investigator's appreciation, except the anti-acne treatment Epiduo and former cosmetic routine)
* oral treatment of retinoids during the six previous months of the study
* any change in hormonal treatment (including contraceptive) during the three previous months of the study or subject under Androcur® generic) treatments since less than six months
* professional facial care during the study or within the previous month
* subject manipulating her/ his acne lesions
* excessive exposure to sunlight or UV-rays within the previous month
12 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cosmetique Active International
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anna Czermanska
Role: STUDY_DIRECTOR
Eurofins
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Studio Dermatologia i Kosmetyka
Malbork, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LRP20026-EFFACLAR SENSIBIOME
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.